

June 9, 2017

Dear Shareholders

Christophe Weber
President and Representative Director
Takeda Pharmaceutical Company Limited
1-1, Doshomachi 4-chome
Chuo-ku, Osaka

Partial Correction to the Reference Document attached to the Notice of Convocation of
the 141st Ordinary General Meeting of Shareholders

Takeda Pharmaceutical Company Limited (the “Company”) hereby reports that there are parts to be corrected in the Reference Document attached to the Notice of Convocation of the 141st Ordinary General Meeting of Shareholders (the “Notice”) and that the Company therefore decided to make corrections to the said parts as described herein below.

1. Correction parts:

The number of the nationalities and members of the Takeda Executive Team (“TET”) members described in the “(4) Comment to the effect that the education and promotion of executives is not being sufficiently done inside the Company, and as such, the Company is forced to rely on external candidates, which require high costs” set forth on page 20 of the Notice

2. Contents of the correction:

Before correction	After correction
The TET, ..., is one of the most diverse leadership teams in the industry with <u>9</u> nationalities out of <u>13</u> members.	The TET, ..., is one of the most diverse leadership teams in the industry with <u>8</u> nationalities out of <u>14</u> members.

[End of document]